Sanofi and GSK Initiate P-III Clinical Study of their COVID-19 Vaccine

 Sanofi and GSK Initiate P-III Clinical Study of their COVID-19 Vaccine

Sanofi and GSK Initiate P-III Clinical Study of their COVID-19 Vaccine

Shots:

  • The companies have started enrollment of patients in a P-III clinical study to assess the safety, efficacy & immunogenicity of COVID-19 vaccine candidate vs PBO in 35,000+ volunteers aged ≥ 18yrs. from multiple countries including the US
  • The 1EP& 2EP of the study is to prevent symptomatic & asymptomatic infection respectively. A two-stage study is designed to assess the efficacy of vaccine targeting D.614 virus & B.1.351 variant in diverse geographies with multiple circulating variants
  • The booster study is expected to be initiated in the coming wks. to complement the P-III study. The company is expecting the approval of the vaccine in Q4’21, manufacturing will begin in the coming wks.

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Evaluate Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post